Shares in Noxopharm Ltd (ASX:NOX) surged on Tuesday after the biotech unveiled new data supporting the cancer-fighting potential of its Sofra platform, adding further momentum to the growing investor focus on next-generation immuno-oncology therapies.
Noxopharm shares closed 43% higher at 8.6 cents, lifting the company’s market value to roughly $18.4 million, after unveiling new preclinical results tied to its Sofra technology platform and a novel approach to activating the immune system against cancer.
While still at an early stage, the announcement lands amid a broader push across the biotech industry to find new ways of improving immuno-oncology outcomes beyond the current generation of checkpoint inhibitors and targeted therapies.
For years, cancer immunotherapy has been dominated by drugs designed to release the immune system’s “brakes”, allowing T-cells to attack tumours more aggressively. Treatments from companies such as Merck & Co. and Bristol Myers Squibb reshaped oncology markets and generated tens of billions of dollars in annual sales.
But response rates remain inconsistent across many cancer types, and researchers continue searching for ways to stimulate broader immune activity or improve the effectiveness of existing treatments.
That is where Noxopharm believes its TLR8 program may fit.
A different immunotherapy angle
The company’s Sofra platform focuses on Toll-like receptors, or TLRs — immune system sensors that help detect threats and trigger inflammatory responses.
Noxopharm is developing short oligonucleotides designed to amplify the activity of Toll-like receptor 8 (TLR8), which has become an increasingly important target in cancer research.
According to the company, one proprietary Sofra oligonucleotide boosted immune activation by more than 200-fold when combined with a clinical-stage TLR8 agonist in human skin biopsy experiments.
A separate animal study showed the immune response increasing almost three-fold when the oligonucleotide was added alongside a TLR8 agonist.
Rather than replacing standard cancer therapies, Noxopharm sees the approach as complementary — potentially enhancing the effectiveness of chemotherapy, radiotherapy or other immunotherapies through stronger immune activation.
The company says the work stems from a deeper understanding of how TLR8 biology is naturally regulated, with associated findings recently published in Nature Immunology and supporting preprint research.
Immuno-oncology keeps expanding
Despite volatility across biotech markets over the past two years, immuno-oncology remains one of the sector’s largest and most heavily funded therapeutic areas. Noxopharm cited forecasts projecting the market could grow from US$35 billion in 2025 to US$185 billion by 2035.
That growth has fuelled increasing interest in therapies capable of activating the innate immune system — the body’s first-line immune response — rather than relying solely on adaptive immune pathways targeted by many current blockbuster drugs.
TLR-based therapies have drawn attention before, though previous approaches have struggled with safety concerns, toxicity or inconsistent efficacy. Noxopharm argues its amplification strategy could offer a more targeted and controllable method of activating TLR8 without simply escalating agonist potency.
The company said its technology is protected by a granted US patent and will now move into further testing using humanised TLR8 mouse models and additional cancer studies over the coming months.
Investors respond to differentiated data
Tuesday’s sharp share price move also reflects the market’s sensitivity to meaningful scientific milestones in small-cap biotech.
After an extended period in which many early-stage healthcare stocks struggled to attract capital, investors have become increasingly selective, rewarding companies that can show differentiated platforms, strong mechanistic rationale or evidence of broader commercial potential.
Noxopharm chief executive Dr Olivier Laczka said the results supported a “new and different approach” to addressing unmet needs in cancer treatment and highlighted the company’s experience in immune-modulating drug development.
There is still a long path between promising preclinical data and commercial success. But with immunotherapy continuing to dominate oncology investment flows globally, even incremental advances in immune activation technology are attracting close attention.
For Noxopharm, the latest data has at least pushed the company back onto investors’ radar — and highlighted how quickly sentiment can shift when biotech companies deliver results that hint at something genuinely distinct.